Intended for healthcare professionals


NICE hears appeals over dementia drugs

BMJ 2006; 333 doi: (Published 20 July 2006) Cite this as: BMJ 2006;333:165
  1. Zosia Kmietowicz
  1. London

    The National Institute for Health and Clinical Excellence (NICE) last week heard five appeals over two days against its decision to restrict the use of drug treatments for Alzheimer's disease to patients with moderate stages of the condition.

    Embedded Image

    The Alzheimer's Society organised a demonstration in June against NICE's revised guidance on dementia drugs

    Credit: MARK THOMAS

    In its original guidance, issued in January 2001, NICE recommended that the drugs donepezil, rivastigmine, and galantamine could be prescribed for people with mild and moderate stages of the disease, defined as having a score of 12 …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription